Molecular Diagnosis of Systemic Autoinflammatory Diseases — SAIDiag  

Genetic Disease Clinical Trial

Official title: Molecular Diagnosis of Systemic Autoinflammatory Diseases

Status Recruiting

Clinical Trial Summary

Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of patients with SAIDs.

Clinical Trial Description

SAIDs are characterized by long dormant periods with no or only minor clinical symptoms interrupted by febrile crises accompanied by serous and synovial membrane inflammation that spontaneously resolves. Over the last decades, more than 50 genes encoding key components of the innate immune system have been identified to be involved in the pathophysiology of SAIDs, with both germline and somatic mosaic variations. When disease-causing variations are identified, specific biotherapies are proposed depending on the involved gene and pathway. However, despite these scientific advances, most SAIDs (70%) are of unknown etiology, the diagnosis is made with significant delay, and no targeted therapy can be suggested. This project aims to generate specific understanding and develop strategies for SAID patients with unknown etiology. The investigators aim to advance our understanding of SAIDs pathophysiology, find the disease-causing gene variations and identify the involved cellular pathways that should accelerate correct diagnosis and personalize treatment. ;

Related Conditions & MeSH terms

• Genetic Disease
• Genetic Diseases, Inborn
• Inflammatory Disease
• Molecular Sequence Variation
• Somatic Mutation

• NCT number: NCT05364294
• Study type: Observational
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Contact: Irina GIURGEA
• Phone: +33144735295
• Email: irina.giurgea@inserm.fr
• Status: Recruiting
• Start date: May 18, 2022
• Completion date: May 2, 2033